




**New Hampshire Department of Health and Human Services**

**Substance Use Disorder Treatment and Recovery Access  
Section 1115(a) Research and Demonstration Waiver**

---

**Annual Post Award Forum - MCAC  
December 9, 2019**

# Agenda

- 
- Overview**
  - Timeline of Significant Deliverables**
  - Timeline of Future Deliverables**
  - Next Steps**
  - Questions**

# Overview

The New Hampshire Department of Health and Human Services requested a Substance Use Disorder Treatment and Recovery Access Section 1115(a) Demonstration Waiver to allow New Hampshire to provide Medicaid payments for individuals receiving substance use disorder (SUD) services in an Institution for Mental Disease (IMD). This request will further the objectives of Title XIX by increasing access to residential SUD treatment services for adults and adolescents in New Hampshire.

Specifically, New Hampshire requested that:

- 1) CMS waive Section 1905(a)(29)(B), 42 CFR 438.6(e), and 42 CFR 435.1010 to allow a waiver of the IMD exclusion for Medicaid-eligible individuals aged 21 to 64 receiving residential substance use disorder (SUD) treatment in an IMD for as long as is medically necessary.
- 2) CMS expand the exception to the IMD exclusion in 42 CFR 441.11(c)(5) to the provider type Comprehensive SUD program, as described in He-W 513.02 (b) to allow New Hampshire to claim federal financial participation (FFP) for individuals under 21 receiving residential substance use disorder treatment in these facilities for long as is medically necessary.

# Timeline of Significant Deliverables

## July 10, 2018

- Demonstration Approved
- FFP for expenditures began
- SUD Implementation Protocol approved

## October 2018

- First Annual Post-Award Forum 10/15/2018

## April 2019

- Initial Evaluation Plan Design submitted to CMS

## May 2019

- Final Evaluation Plan submitted to and approved by CMS

## October 2019

- First Annual report submitted to CMS for Demonstration Year 1

## December 2019

- Second Annual Post-Award Forum 12/09/2019

# Timeline of Future Deliverables

## 2020

- Regular quarterly monitoring reports, annual report, and annual post-award forum

## 2021

- March – Mid-Point Assessment

## 2022

- June – Draft Interim Evaluation Report  
– Request to extend demonstration

## 2023

- March – Draft Close-Out Operational Report
- June – End of demonstration

## 2024

- December- Draft Summative Evaluation Report

## 2025

- March - Final Evaluation Report

# Next Steps

- Potentially amending to include treatment provided to individuals with SMI
- On going data collection and analysis of the Prescription Drug Monitoring Program (PDMP)

# Questions and Answers